infection-congress-2017-posters-accepted-abstracts

11 / 29

Page 56
Notes:
conferenceseries.com
Volume 5, Issue 2 (Suppl) J Infect Dis Ther 2017
ISSN: 2332-0877, JIDT an open access journal Infection Congress 2017
May 11-12, 2017
May 11-12, 2017 Barcelona, Spain
4th International Congress on
Infectious Diseases
Dalia Salem et al., J Infect Dis Ther 2017, 5:2 (Suppl)
Detection of antimicrobial resistance genes of Helicobacter pylori strains to clarithromycin, metronidazole,
amoxicillin and tetracycline among Egyptian patients
Dalia Salem1, Manal Diab1, Ahmed El-Shenawy1, Maged El-Ghannam1, Moustafa Abdelnasser2, Mohamed Shahin1, Mahmoud Abdel-Hady2, Effat El-Sherbini 1
and Mohamed Saber1
1Theodor Bilharz Research Institute, Egypt
2Al-Azhar University, Egypt
Antibiotic resistance of Helicobacter pylori (H.pylori) treatment is on the rise and is affecting the efficacy of current used therapeutic
regimens. The choice of empiric treatment should be anticipated on the bases of antibiotic resistance rates. Therefore, we aimed to
enhance the understanding of antimicrobial resistance rates of H.pylori strains recovered from patients in Theodor Bilharz Research
Institute Hospital in Egypt, as a mandatory step before starting treatment. Mutant genes conferring metronidazole, amoxicillin,
and clarithromycin and tetracycline resistance were detected in 60 H. pylori strains recovered from patients who underwent upper
endoscopic examination. Patients were considered to be infected with H. pylori when rapid urease test and detection of 16S rRNA
in gastric biopsies recorded positive. Molecular detection of resistant genes to metronidazole (rdx gene) and amoxicillin (pbp1A
gene) was carried out by conventional PCR followed by sequencing of PCR products. H. pylori resistance to metronidazole and
amoxicillin were 25% and 18.3% respectively. While for clarithromycin and tetracycline, point mutations in 23S rRNA types A2142G
and A2143G and in 16S rRNA of H. pylori were assessed by real time PCR assay respectively. Resistance mutant genes were found to
be 6.7% of clarithromycin and 1.7% of tetracycline. Combined resistance rates to metronidazole and amoxicillin was 11.6% followed
by metronidazole and clarithromycin 5%, while patterns of clarithromycin and amoxicillin 1.6%, metronidazole, clarithromycin
and amoxicillin 1.6% were revealed. In conclusion, data concerning antimicrobial resistance genes play an important role in empiric
treatment of H. pylori infection. According to our results H. pylori resistance to metronidazole and amoxicillin was relatively high.
Clarithromycin is still a good option for first line anti- H. pylori treatment. Combined resistant strains are emerging and may have an
effect on the combination therapy.
Biography
Dalia Salem is a Lecturer of Medical Microbiology at Theodor Bilharz Research Institute- Egypt. Her special research interest and expertise is in “Detection of
emerging mechanisms of multi-drug-resistant bacteria and their susceptibility patterns to novel antibiotics in addition to antimicrobial resistant genes and virulence
markers in Helicobacter pylori-related infections”.